biomarker is “a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or a condition or disease,” (NCI) such as cancer. Biomarkers typically differentiate an affected patient from a person without the disease. The alterations can be due to many factors, including germline or somatic mutations, transcriptional changes, and post‐translational modifications. There is a tremendous variety of biomarkers, which can include proteins (e.g., an enzyme or receptor), nucleic acids (e.g., a microRNA or other non‐coding RNA), antibodies, and peptides, among other categories. In oncology, biomarkers are substances released by a tumor or a particular bodily reaction that signal the existence of cancer. By utilizing a variety of genomes and proteomics techniques, biomarkers enable early cancer detection and fast noninvasive diagnosis. Applications for biomarkers include prognostics, customized medicine, medication development, and cancer diagnosis. The worldwide market is expanding due in part to the growing need for biomarkers in medication development and customized medicine. According to the World Health Organization, cancer is one of the primary causes of mortality globally, accounting for around 10 million deaths or nearly one in every six deaths in 2020. Cancers of the lung, breast, colon, rectum, and prostate are among the most frequent cancers.
Ovarian cancer is currently the sixth most common cause of mortality for women with cancer worldwide, per a report published in the Journal of Ovarian Research. In more than 70% of cases, this cancer is discovered at an advanced stage. When it comes to ovarian and endometrial cancer detection, the human epididymis protein 4 biomarker test, or HE4 test, is thought to be the most accurate and dependable test available.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/cancer-biomarkers-market/
Global Cancer Biomarkers Market – Competitive Insights
On February 8, 2023, Pacific Biomarker merged with Neomed Labs.
On February 6, 2023, Novartis acquired MorphoSys for USD 2.9 billion in a bid to grow its oncology footprint.
On May 22, 2019, Biotech Support Group (BSG) entered into a research collaboration with Leiden University Medical Center (LUMC) to develop Stromal conditioning biomarkers in cancer (protein biomarker).
Some of the Key Players in the Global Cancer Biomarkers Market include –
- Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- Abbott Laboratories
- Exact Sciences
- Meso Scale Diagnostics LLC
- Seegene Technologies Inc.
- Siemens Healthineers
Global Cancer Biomarkers Market – Growth Drivers
The cancer biomarkers are used in the diagnosis and treatment of cancer. One of the prominent factors driving the growth of the global cancer biomarkers market is rising incidences of cancer all around the world. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, with approximately 10 million fatalities expected in 2020, for almost one in every six deaths. The aging population Is another element propelling the global market for cancer biomarkers. Aging populations are more vulnerable to serious illnesses like cancer. These individuals therefore need the best care and prompt treatment for these illnesses. Furthermore, the global market for cancer biomarkers is expected to rise as a result of technical improvements. Thus, the global market’s development of novel cancer biomarkers is aided by the use of innovative technologies.
Global Cancer Biomarkers Market -Restraints
One of the factors restricting the demand for these biomarkers globally is the absence of reimbursement policies for biomarker testing in emerging and developed nations, even though the incidence of cancer is rising globally and the number of patients requiring diagnostic tests is growing. The high cost of cancer diagnosis and treatment in developing nations is a significant issue impeding the market’s expansion. As a result, fewer patients are having biomarker testing done, and patients are becoming more interested in alternative, less expensive detection methods. One of the most important concerns for service providers is sample collection, which is followed by sample access. To prevent any loss, these samples must be stored under ideal circumstances and undergo strict quality monitoring. Additionally, various samples are needed for the procedures of risk assessment, screening, diagnosis, and monitoring.
Global Cancer Biomarkers Market -Opportunities
Personalized medicine determines which course of treatment is best for each patient. In certain aspects of personalized medicine, cancer biomarkers are crucial. The detection of these illnesses is made possible by the consumables used in cancer biomarker testing. Diagnostic tools for cancer biomarkers are being utilized in conjunction with many experimental treatments. Therefore, it is anticipated that participants in the market would have possibilities for expansion in the personalized medicine space.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/cancer-biomarkers-market/
Global Cancer Biomarkers Market-Geographical Insights
In 2021, North America held a market share of over 30%, dominating the global market for cancer biomarkers. Throughout the forecast period, it is anticipated to hold a sizable portion of the global market for cancer biomarkers. It is anticipated that the region’s market for cancer biomarkers would be driven by the high number of cancer patients in the United States and Canada as well as a rise in research and development efforts about different kinds of biomarkers. During the projected period, Europe is anticipated to remain a highly desirable region in the global cancer biomarkers market. Throughout the projected period, the market is anticipated to be driven by the region’s rising cancer incidence and prevalence. It is also expected that during the projection period, the Asia-Pacific market for cancer biomarkers will expand significantly. This can be attributed to the growth in disposable income, the speed at which the region is urbanizing, the expansion of the infrastructure for health care, and the distribution and cooperation methods used by the regional players.
Cancer Biomarkers Market– Key Development
- On June 26, 2023, the FDA launched programs to reduce the risk of cancer biomarker testing.
- On April 8, 2021, F. Hoffmann-La Roche Ltd. (Switzerland), Launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various cancer types.
- On December 9, 2020, Thermo Fisher Scientific (US) received FDA approval for NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
- On April 15, 2020, Qiagen N.V. (Netherlands) Launched the therascreen BRAF test as a companion diagnostic to a BRAFTOVI (encorafenib) based regimen in metastatic colorectal cancer.